Important legal notice
Contact   |   Search   

Sixth Framework Programme MAJOR PROJECTS LIBRARY - What's New?


The library contains an overview of Integrated Projects (IPs) and Networks of Excellence (NoEs) selected so far. The What's New? section features projects with new information such as links to websites, articles etc.

NB: The library does not yet include Information Society Technologies, or the parts of Aeronautics and Space, and Sustainable Surface Transport covered by the Energy and Transport DG.

Click a title below and then scroll down the page to see projects for that thematic priority.

Major Projects Library Home Page
Number of projects in the library
Life sciences, genomics and biotechnologies for health
Nanotechnologies and nanoscience, knowledge-based multifunctional materials, and new production processes and devices
Aeronautics and space
Food quality and safety
Sustainable energy systems
Sustainable surface transport
Global change and ecosystems
Citizens and governance in a knowledge-based society
European Atomic Energy Community - Euratom

Title: Curing autoimmune disease. A translational approcah to autoimmune diseases in the post-genomic era using inflammatory arthritis and myositis as prototypes and learning examples.
Acronym:   AUTOCURE
What's new:   New project
Project summary:   Objective: To transform knowledge obtained from molecular research particularly within genomics, into a cure in an increasing number of patients suffering from inflammatory rheumatic diseases. Rheumatoid arthritis (RA) is used as a prototype since this disease offers unique opportunities to define and evaluate new therapies. State of the art and beyond: Development of the first generation of targeted therapies (anti-TNF and anti-IL-1) in chronic inflammatory disease used RA as the prototype disease after work from European investigators included in the current IP. This work demonstrated (i) that targeted therapies can be efficient and (ii) that cure is still not achieved, but is within reach through a strong international consortium covering translational research and molecular technology. Work plan: -Potential key molecular mechanisms determining the course of RA and myositis are defined from genetic studies in humans, from relevant animal models and from basic cell and molecular biology. - Predictors of disease development and therapeutic responses, enabling future individualised therapies, are developed with the help of our unique large patient cohorts and, biobanks.. - Development and evaluation of new therapies is performed using combinations of novel molecular tools and precise definition of disease phenotypes. Impact of the project: We aim to produce (i) an increased understanding of the causes of RA and myositis enabling better prevention; (ii) new potential targets for therapy in arthritis and myositis, which can be further tested in other rheumatic inflammatory diseases; (iii) a prototype system for translational research in Europe, enabling collaborative development of targeted therapies in many inflammatory diseases and enabling European SMEs to rapidly develop ideas and patents into targeted therapies in inflammatory diseases.

Additional project information:   Project website 

Title: Genomics, mechanisms and treatment of addiction
Acronym:   GENADDICT
What's new:   New project
Project summary:   Addiction is a brain disease, common in Europe, with deleterious consequences on individual physical and psychological health, and serious societal and economic consequences through criminality and violence, decreased productivity and increased healthcare costs. In every family, in a lifetime one can identify someone who has suffered from addiction; alcohol, nicotine or illicit drug use affects many people. Over 20 years there has been little advance in the drug treatment for addiction, with most new treatments addressing physical drug withdrawal rather than treating drug craving and relapse. The contribution of genetic influences to addiction liability has been recently recognised but the identification of genetic risk factors and genes involved in the molecular basis of addiction is a new major challenge for the post-genomic era. This project is a collaboration between basic science groups, one SME and a leading biotechnology company devoted to human studies on the role of genes in complex diseases. This public-private partnership brings together a highly innovative genealogical led human genetics approach and a team of researchers with Europe¹s best genomic mouse models. The core of the research effort will be the identification of genes associated with drug addiction using an unbiased genome-wide approach. The strong environmental component in the etiology of drug addiction has presented a particularly difficult problem for genetic studies of this brain disorder in the past. The groups of this Consortium propose to meet this difficult challenge by combining powerful animal genetics and gene profiling strategies with a human genetic approach that is relatively resistant to environmental modifications of the drug addiction phenotype. Genes identified in this project will help to elucidate dysfunction of genetic pathways in the addicted brain and provide new targets for the development of novel therapies.

This integrated project started on 1 January 2005, and lasts 60 months. It involves 8 participants from 7 EU countries.

Additional project information:   Project website 

Title: Optimized Procedures and Techniques for IMprovement of Approach and Landing
Acronym:   OPTIMAL
What's new:   Website
Project summary:   As traffic grows steadily, airport congestion and environmental impacts become a mounting problem and already a limiting factor at some airports. OPTIMAL is an air-ground co-operative project which is aiming to define and validate innovative procedures for the approach and landing phases of aircraft and rotorcraft in a pre-operational environment. The goal is to minimise external aircraft/rotorcraft noise nuisance and increase the ATM capacity while maintaining and even improving safety. Those achievements will be enabled by new precision approach landing aids (MLS, SBAS, GBAS), more accurate navigation means (RNP 0.1) and enhanced airborne systems, such as FLS, for Non-Precision Approaches. The target time frame for the operational implementation of the OPTIMAL proposed operational concept is 2010 and beyond, it will therefore participate in reaching the targets for airport capacity developments identified in the ATM 2000+ Strategy and in the ACARE Strategic Agenda.The work to be conducted during the 4 years project is ranging from the elaboration of the operational concept up to simulations and pre-operational flight trials implying effective modifications of avionics onboard aircraft and rotorcraft and ground systems. On the ground system side special attention will be placed on the new tools which will be necessary for Air Traffic Controller to efficiently and safely manage the OPTIMAL procedures.The OPTIMAL project team is composed, among others, by the major european aircraft, rotorcraft and airborne & ground systems manufacturers, major european research institutes, various ATS providers, and key experts in procedures specification and validation exercise. This team quite early identified the key methods and tools to manage adequately all work-packages of the project. Particular emphasis is made on the project management organisation, the methodology to define the procedures, the validation methodology.

Additional project information:   Project website 

Title: The nitrogen cycle and its influence on the European greenhouse gas balance
Acronym:   NitroEurope
What's new:   New project
Project summary:   The NitroEurope IP - or NEU for short - addresses the major question: What is the effect of reactive nitrogen (Nr) supply on net greenhouse gas budgets for Europe? The objectives are to:
* establish robust datasets of N fluxes and net greenhouse-gas exchange (NGE) in relation to C-N cycling of representative European ecosystems, as a basis to investigate interactions and assess long-term change,
* quantify the effects of past and present global changes (climate, atmospheric composition, land-use/land-management) on CN cycling and NGE,
* simulate the observed fluxes of N and NGE, their interactions and responses to global change/land-management decisions, through refinement of plot-scale models,
* quantify multiple N and C fluxes for contrasting European landscapes, including interactions between farm-scale management, atmospheric and water dispersion, and consideration of the implications for net fluxes and strategies,
* scale up Nr and NGE fluxes for terrestrial ecosystems to regional and European levels, considering spatial variability and allowing assessment of past, present and future changes,
* assess uncertainties in the European model results and use these together with independent measurement/inverse modelling approaches for verification of European N2O and CH4 inventories and refinement of IPCC approaches.
These objectives are met by a programme that integrates:
1) an observing system for N fluxes and pools [Component 1]
2) a network of manipulation experiments [Component 2]
3) plot-scale C-N modelling [Component 3]
4) landscape analysis [Component 4]
5) European up-scaling [Component 5] and
6) uncertainty and verification of European estimates [Component 6].
In addition to that, the project organisation comprises cross-cutting activities addressing management, databases, training and dissemination.
NEU will advance the fundamental understanding of C-N interactions at different scales and deliver: process-based models, landscape-level assessments, European maps of C-N pools, Nr fluxes and NGE, and independent verification of GHG inventories, as required under the Kyoto Protocol.

Additional project information:   Project website 


Title: Task-force in Europe for Drug Development for the Young
Acronym:   TEDDY
What's new:   New project
Project summary:   The Task-force in Europe for Drug Development for the Young (TEDDY) is a Network of Excellence funded under the Sixth EU Framework Programme for Research and Technological Development (FP6). The project started in June 2005 and is expected to run until 2010. It involves 17 partners from 9 EU countries, Romania and Israel. The overall aim of TEDDY is promoting the availability of safe and effective medicines for children in Europe by integrating existing expertise and good practices, as well as stimulating further developments. Today, no more than 30% of marketed drugs in Europe can be considered safe and effective with respect to their paediatric use, as a consequence of insufficient efforts in dedicated biomedical research. This gap is rooted, on the one hand, in the complexity of scientific and ethical issues linked to the design and execution of clinical trials involving children, and on the other hand, on a perception of poor profitability which seems to prevent pharmaceutical companies from investing significantly in this sector. However, along with other age groups, children as well should benefit from breakthroughs in genomics, biotechnology, pharmacology and therapeutics. The European Legislator is developing a Regulation on medicinal products for paediatric use which is likely to improve significantly the current situation. Within this general institutional framework, and in synergy with other processes and actors, TEDDY wishes to dwell on the development of a new research matrix that integrates scientific domains, assesses the impact of findings and monitors policy implementation. TEDDY aims at optimising the paediatric use of current drugs and promoting the development of new drugs.

Additional project information:   Project website